REFERENCES
1. Williamson SL, Christodoulou J. Rett syndrome: new clinical and molecular insights. Eur J Hum Genet 2006;14:896-903.
2. Burd L, Randall T, Martsolf JT, Kerbeshian J. Rett syndrome symptomatology of institutionalized adults with mental retardation: comparison of males and females. Am J Ment Retard 1991;95:596-601.
3. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185-8.
4. Evans JC, Archer HL, Colley JP, et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet 2005;13:1113-20.
5. Philippe C, Amsallem D, Francannet C, et al. Phenotypic variability in Rett syndrome associated with FOXG1 mutations in females. J Med Genet 2010;47:59-65.
6. Pejhan S, Rastegar M. Role of DNA methyl-CpG-binding protein MeCP2 in Rett syndrome pathobiology and mechanism of disease. Biomolecules 2021;11:75.
7. Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol 2018:8.
9. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001;27:327-31.
10. Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY. An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 2013;152:984-96.
11. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007;315:1143-7.
12. Zhou H, Wu W, Zhang Y, et al. Selective preservation of cholinergic MeCP2 rescues specific Rett-syndrome-like phenotypes in MeCP2(stop) mice. Behav Brain Res 2017;322:51-9.
13. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci 2009;29:5051-61.
14. Alvarez-Saavedra M, Sáez MA, Kang D, Zoghbi HY, Young JI. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum Mol Genet 2007;16:2315-25.
15. Lioy DT, Garg SK, Monaghan CE, et al. A role for glia in the progression of Rett’s syndrome. Nature 2011;475:497-500.
16. Kong Y, Li QB, Yuan ZH, et al. Multimodal neuroimaging in Rett syndrome with MECP2 mutation. Front Neurol 2022;13:838206.
17. Shiohama T, Tsujimura K. Quantitative structural brain magnetic resonance imaging analyses: methodological overview and application to Rett syndrome. Front Neurosci 2022;16:835964.
18. Rivera AD, Chacon-De-La-Rocha I, Pieropan F, Papanikolau M, Azim K, Butt AM. Keeping the ageing brain wired: a role for purine signalling in regulating cellular metabolism in oligodendrocyte progenitors. Pflugers Arch 2021;473:775-83.
19. Elbaz B, Popko B. Molecular control of oligodendrocyte development. Trends Neurosci 2019;42:263-77.
20. Kriaucionis S, Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res 2004;32:1818-23.
21. Olson CO, Zachariah RM, Ezeonwuka CD, Liyanage VR, Rastegar M. Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements. PLoS One 2014;9:e90645.
22. Sandweiss AJ, Brandt VL, Zoghbi HY. Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies. Lancet Neurol 2020;19:689-98.
23. Rodrigues DC, Mufteev M, Ellis J. Regulation, diversity and function of MECP2 exon and 3’UTR isoforms. Hum Mol Genet 2020;29:R89-99.
25. Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008;70:1313-21.
26. Goto T, Monk M. Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev 1998;62:362-78.
27. Trappe R, Laccone F, Cobilanschi J, et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 2001;68:1093-101.
28. Stenson PD, Ball EV, Mort M, et al. Human gene mutation database (HGMD): 2003 update. Hum Mutat 2003;21:577-81.
29. Lee SS, Wan M, Francke U. Spectrum of MECP2 mutations in Rett syndrome. Brain Dev 2001;23 Suppl 1:S138-43.
30. Krishnaraj R, Ho G, Christodoulou J. RettBASE: Rett syndrome database update. Hum Mutat 2017;38:922-31.
31. Brown K, Selfridge J, Lagger S, et al. The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum Mol Genet 2016;25:558-70.
32. Nikitina T, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Grigoryev SA, Woodcock CL. MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J Biol Chem 2007;282:28237-45.
33. Lyst MJ, Ekiert R, Ebert DH, et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci 2013;16:898-902.
34. Pidcock FS, Salorio C, Bibat G, et al. Functional outcomes in Rett syndrome. Brain Dev 2016;38:76-81.
35. Cuddapah VA, Pillai RB, Shekar KV, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet 2014;51:152-8.
36. Mellén M, Ayata P, Heintz N. 5-hydroxymethylcytosine accumulation in postmitotic neurons results in functional demethylation of expressed genes. Proc Natl Acad Sci U S A 2017;114:E7812-21.
37. Sperlazza MJ, Bilinovich SM, Sinanan LM, Javier FR, Williams DC Jr. Structural basis of MeCP2 distribution on Non-CpG methylated and hydroxymethylated DNA. J Mol Biol 2017;429:1581-94.
38. Liu K, Xu C, Lei M, et al. Structural basis for the ability of MBD domains to bind methyl-CG and TG sites in DNA. J Biol Chem 2018;293:7344-54.
39. Young JI, Hong EP, Castle JC, et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci U S A 2005;102:17551-8.
40. Brito DVC, Gulmez Karaca K, Kupke J, Frank L, Oliveira AMM. MeCP2 gates spatial learning-induced alternative splicing events in the mouse hippocampus. Mol Brain 2020;13:156.
41. Gonzales ML, Adams S, Dunaway KW, LaSalle JM. Phosphorylation of distinct sites in MeCP2 modifies cofactor associations and the dynamics of transcriptional regulation. Mol Cell Biol 2012;32:2894-903.
42. Kleene R, Loers G, Schachner M. The KDET Motif in the intracellular domain of the cell adhesion molecule L1 interacts with several nuclear, cytoplasmic, and mitochondrial proteins essential for neuronal functions. Int J Mol Sci 2023;24:932.
43. Wong JJ, Gao D, Nguyen TV, et al. Intron retention is regulated by altered MeCP2-mediated splicing factor recruitment. Nat Commun 2017;8:15134.
44. Chen T, Cai SL, Li J, et al. Mecp2-mediated epigenetic silencing of miR-137 contributes to colorectal adenoma-carcinoma sequence and tumor progression via relieving the suppression of c-Met. Sci Rep 2017;7:44543.
45. Gao Y, Su J, Guo W, et al. Inhibition of miR-15a promotes BDNF expression and rescues dendritic maturation deficits in MeCP2-deficient neurons. Stem Cells 2015;33:1618-29.
46. Nomura T, Kimura M, Horii T, et al. MeCP2-dependent repression of an imprinted miR-184 released by depolarization. Hum Mol Genet 2008;17:1192-9.
47. Chen Y, Shin BC, Thamotharan S, Devaskar SU. Differential methylation of the micro-RNA 7b gene targets postnatal maturation of murine neuronal Mecp2 gene expression. Dev Neurobiol 2014;74:407-25.
48. Cheng TL, Wang Z, Liao Q, et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev Cell 2014;28:547-60.
49. Mellios N, Feldman DA, Sheridan SD, et al. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling. Mol Psychiatry 2018;23:1051-65.
50. Mellios N, Woodson J, Garcia RI, et al. β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 2014;111:9947-52.
51. Urdinguio RG, Fernandez AF, Lopez-Nieva P, et al. Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics 2010;5:656-63.
52. Horvath PM, Piazza MK, Kavalali ET, Monteggia LM. MeCP2 loss-of-function dysregulates microRNAs regionally and disrupts excitatory/inhibitory synaptic transmission balance. Hippocampus 2022;32:610-23.
53. Vashi N, Justice MJ. Treating Rett syndrome: from mouse models to human therapies. Mamm Genome 2019;30:90-110.
54. Tarquinio DC, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol 2015;53:402-11.
55. Chen Y, Yu J, Niu Y, et al. Modeling rett syndrome using TALEN-Edited MECP2 mutant cynomolgus monkeys. Cell 2017;169:945-55.e10.
56. Grattan-Smith JD, Chow J, Kurugol S, Jones RA. Quantitative renal magnetic resonance imaging: magnetic resonance urography. Pediatr Radiol 2022;52:228-48.
57. Mahmood A, Bibat G, Zhan AL, et al. White matter impairment in Rett syndrome: diffusion tensor imaging study with clinical correlations. AJNR Am J Neuroradiol 2010;31:295-9.
58. Allemang-Grand R, Ellegood J, Spencer Noakes L, et al. Neuroanatomy in mouse models of Rett syndrome is related to the severity of Mecp2 mutation and behavioral phenotypes. Mol Autism 2017;8:32.
59. Akaba Y, Shiohama T, Komaki Y, et al. Comprehensive volumetric analysis of Mecp2-null mouse model for Rett syndrome by T2-weighted 3D magnetic resonance imaging. Front Neurosci 2022;16:885335.
60. Takeguchi R, Kuroda M, Tanaka R, et al. Structural and functional changes in the brains of patients with Rett syndrome: a multimodal MRI study. J Neurol Sci 2022;441:120381.
61. Zhao Y, Yang L, Gong G, Cao Q, Liu J. Identify aberrant white matter microstructure in ASD, ADHD and other neurodevelopmental disorders: a meta-analysis of diffusion tensor imaging studies. Prog Neuropsychopharmacol Biol Psychiatry 2022;113:110477.
62. Wang J, Wang Z, Zhang H, et al. White matter structural and network topological changes underlying the behavioral phenotype of MECP2 mutant monkeys. Cereb Cortex 2021;31:5396-410.
63. Concha L. A macroscopic view of microstructure: using diffusion-weighted images to infer damage, repair, and plasticity of white matter. Neuroscience 2014;276:14-28.
64. Graciarena M, Seiffe A, Nait-Oumesmar B, Depino AM. Hypomyelination and oligodendroglial alterations in a mouse model of autism spectrum disorder. Front Cell Neurosci 2018;12:517.
65. Carter JC, Lanham DC, Pham D, Bibat G, Naidu S, Kaufmann WE. Selective cerebral volume reduction in Rett syndrome: a multiple-approach MR imaging study. AJNR Am J Neuroradiol 2008;29:436-41.
66. Tani H, Ishikawa N, Kobayashi Y, et al. Anti-MOG antibody encephalitis mimicking neurological deterioration in a case of Rett syndrome with MECP2 mutation. Brain Dev 2018;40:943-6.
67. Zhou X, Liao Y, Xu M, et al. A novel mutation R190H in the AT-hook 1 domain of MeCP2 identified in an atypical Rett syndrome. Oncotarget 2017;8:82156-64.
68. Tokaji N, Ito H, Kohmoto T, et al. A rare male patient with classic Rett syndrome caused by MeCP2_e1 mutation. Am J Med Genet A 2018;176:699-702.
69. Saitsu H, Osaka H, Nishiyama K, et al. A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5. Brain Dev 2012;34:364-7.
70. Kumakura A, Takahashi S, Okajima K, Hata D. A haploinsufficiency of FOXG1 identified in a boy with congenital variant of Rett syndrome. Brain Dev 2014;36:725-9.
71. De Filippis B, Fabbri A, Simone D, et al. Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome. Neuropsychopharmacology 2012;37:1152-63.
72. Juarez A, He D, Richard Lu Q. Oligodendrocyte progenitor programming and reprogramming: toward myelin regeneration. Brain Res 2016;1638:209-20.
73. Akay LA, Effenberger AH, Tsai LH. Cell of all trades: oligodendrocyte precursor cells in synaptic, vascular, and immune function. Genes Dev 2021;35:180-98.
74. Weng Q, Wang J, Wang J, et al. Single-cell transcriptomics uncovers glial progenitor diversity and cell fate determinants during development and gliomagenesis. Cell Stem Cell 2019;24:707-723.e8.
75. Huang W, Bhaduri A, Velmeshev D, et al. Origins and proliferative states of human oligodendrocyte precursor cells. Cell 2020;182:594-608.e11.
76. Kessaris N, Fogarty M, Iannarelli P, Grist M, Wegner M, Richardson WD. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat Neurosci 2006;9:173-9.
77. Jakovcevski I, Filipovic R, Mo Z, Rakic S, Zecevic N. Oligodendrocyte development and the onset of myelination in the human fetal brain. Front Neuroanat 2009;3:5.
78. Cui QL, D'Abate L, Fang J, et al. Human fetal oligodendrocyte progenitor cells from different gestational stages exhibit substantially different potential to myelinate. Stem Cells Dev 2012;21:1831-7.
79. Kuhn S, Gritti L, Crooks D, Dombrowski Y. Oligodendrocytes in development, myelin generation and beyond. Cells 2019;8:1424.
80. Dawson MR, Polito A, Levine JM, Reynolds R. NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci 2003;24:476-88.
81. Xu J, Zhao J, Wang R, et al. Shh and Olig2 sequentially regulate oligodendrocyte differentiation from hiPSCs for the treatment of ischemic stroke. Theranostics 2022;12:3131-49.
82. Wu R, Li A, Sun B, et al. A novel m6A reader Prrc2a controls oligodendroglial specification and myelination. Cell Res 2019;29:23-41.
83. Liu Z, Hu X, Cai J, et al. Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms. Dev Biol 2007;302:683-93.
84. Hornig J, Fröb F, Vogl MR, Hermans-Borgmeyer I, Tamm ER, Wegner M. The transcription factors Sox10 and Myrf define an essential regulatory network module in differentiating oligodendrocytes. PLoS Genet 2013;9:e1003907.
85. Emery B, Agalliu D, Cahoy JD, et al. Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell 2009;138:172-85.
86. Zhu Q, Zhao X, Zheng K, et al. Genetic evidence that Nkx2.2 and Pdgfra are major determinants of the timing of oligodendrocyte differentiation in the developing CNS. Development 2014;141:548-55.
87. Sanchez JC, Zhang L, Evoli S, et al. The molecular basis of selective DNA binding by the BRG1 AT-hook and bromodomain. Biochim Biophys Acta Gene Regul Mech 2020;1863:194566.
88. Matsumoto S, Banine F, Feistel K, et al. Brg1 directly regulates Olig2 transcription and is required for oligodendrocyte progenitor cell specification. Dev Biol 2016;413:173-87.
89. He D, Marie C, Zhao C, et al. Chd7 cooperates with Sox10 and regulates the onset of CNS myelination and remyelination. Nat Neurosci 2016;19:678-89.
90. Wang W, Cho H, Kim D, et al. PRC2 acts as a critical timer that drives oligodendrocyte fate over astrocyte identity by repressing the notch pathway. Cell Rep 2020;32:108147.
91. Dugas JC, Cuellar TL, Scholze A, et al. Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. Neuron 2010;65:597-611.
92. Shin D, Shin JY, McManus MT, Ptácek LJ, Fu YH. Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann Neurol 2009;66:843-57.
93. Wang H, Moyano AL, Ma Z, et al. miR-219 Cooperates with miR-338 in myelination and promotes myelin repair in the CNS. Dev Cell 2017;40:566-582.e5.
94. Buller B, Chopp M, Ueno Y, et al. Regulation of serum response factor by miRNA-200 and miRNA-9 modulates oligodendrocyte progenitor cell differentiation. Glia 2012;60:1906-14.
95. Gonzalez Cardona J, Smith MD, Wang J, et al. Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis. PLoS One 2019;14:e0221747.
96. Huang JY, Wang YX, Gu WL, et al. Expression and function of myelin-associated proteins and their common receptor NgR on oligodendrocyte progenitor cells. Brain Res 2012;1437:1-15.
97. Sharma KD, Alghazali KM, Hamzah RN, et al. Gold nanorod substrate for rat fetal neural stem cell differentiation into oligodendrocytes. Nanomaterials (Basel) 2022;12:929.
98. Pang Y, Zheng B, Fan LW, Rhodes PG, Cai Z. IGF-1 protects oligodendrocyte progenitors against TNFalpha-induced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway. Glia 2007;55:1099-107.
99. McKinnon RD, Waldron S, Kiel ME. PDGF alpha-receptor signal strength controls an RTK rheostat that integrates phosphoinositol 3’-kinase and phospholipase Cgamma pathways during oligodendrocyte maturation. J Neurosci 2005;25:3499-508.
100. Dell’albani P, Kahn M, Cole R, Condorelli D, Giuffrida-stella A, de Vellis J. Oligodendroglial survival factors, PDGF-AA and CNTF, activate similar JAK/STAT signaling pathways. J Neurosci Res 1998;54:191-205.
101. Azim K, Raineteau O, Butt AM. Intraventricular injection of FGF-2 promotes generation of oligodendrocyte-lineage cells in the postnatal and adult forebrain. Glia 2012;60:1977-90.
102. Deverman BE, Patterson PH. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J Neurosci 2012;32:2100-9.
103. Vinukonda G, Hu F, Mehdizadeh R, et al. Epidermal growth factor preserves myelin and promotes astrogliosis after intraventricular hemorrhage. Glia 2016;64:1987-2004.
104. Talbott JF, Cao Q, Bertram J, et al. CNTF promotes the survival and differentiation of adult spinal cord-derived oligodendrocyte precursor cells in vitro but fails to promote remyelination in vivo. Exp Neurol 2007;204:485-9.
105. Nguyen MV, Felice CA, Du F, et al. Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. J Neurosci 2013;33:18764-74.
106. Zhou J, Wu YC, Xiao BJ, Guo XD, Zheng QX, Wu B. Age-related changes in the global DNA methylation profile of oligodendrocyte progenitor cells derived from rat spinal cords. Curr Med Sci 2019;39:67-74.
107. Phan BN, Bohlen JF, Davis BA, et al. A myelin-related transcriptomic profile is shared by Pitt-Hopkins syndrome models and human autism spectrum disorder. Nat Neurosci 2020;23:375-85.
109. Rajman M, Schratt G. MicroRNAs in neural development: from master regulators to fine-tuners. Development 2017;144:2310-22.
110. Good KV, Vincent JB, Ausió J. MeCP2: The genetic driver of rett syndrome epigenetics. Front Genet 2021;12:620859.
111. Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetic regulation in human melanoma: past and future. Epigenetics 2015;10:103-21.
112. Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. Nat Rev Neurosci 2018;19:368-82.
113. Galloway DA, Moore CS. miRNAs as emerging regulators of oligodendrocyte development and differentiation. Front Cell Dev Biol 2016;4:59.
114. Tiane A, Schepers M, Rombaut B, et al. From OPC to oligodendrocyte: an epigenetic journey. Cells 2019;8:1236.
115. AmeliMojarad M, AmeliMojarad M, Pourmahdian A. Circular RNA circ_0051620 sponges miR-338-3p and regulates ADAM17 to promote the gastric cancer progression. Pathol Res Pract 2022;233:153887.
116. Wang G, Zhang Z, Xia C. Long non-coding RNA LINC00240 promotes gastric cancer progression via modulating miR-338-5p/METTL3 axis. Bioengineered 2021;12:9678-91.
117. Guo B, Liu L, Yao J, et al. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. Mol Cancer Res 2014;12:313-21.
118. de Faria O Jr, Cui QL, Bin JM, et al. Regulation of miRNA 219 and miRNA clusters 338 and 17-92 in oligodendrocytes. Front Genet 2012;3:46.
119. Tsujimura K, Irie K, Nakashima H, et al. miR-199a Links MeCP2 with mTOR signaling and its dysregulation leads to rett syndrome phenotypes. Cell Rep 2015;12:1887-901.
120. Nakashima H, Tsujimura K, Irie K, et al. MeCP2 controls neural stem cell fate specification through miR-199a-mediated inhibition of BMP-Smad signaling. Cell Rep 2021;35:109124.
121. Bronstein JM, Tiwari-woodruff S, Buznikov AG, Stevens DB. Involvement of OSP/claudin-11 in oligodendrocyte membrane interactions: Role in biology and disease. J Neurosci Res 2000;59:706-11.
122. Letzen BS, Liu C, Thakor NV, Gearhart JD, All AH, Kerr CL. MicroRNA expression profiling of oligodendrocyte differentiation from human embryonic stem cells. PLoS One 2010;5:e10480.
123. Weise SC, Arumugam G, Villarreal A, et al. FOXG1 Regulates PRKAR2B transcriptionally and posttranscriptionally via miR200 in the adult hippocampus. Mol Neurobiol 2019;56:5188-201.
124. Shyamasundar S, Ramya S, Kandilya D, et al. Maternal diabetes deregulates the expression of Mecp2 via miR-26b-5p in mouse embryonic neural stem cells. Cells 2023;12:1516.
125. Lau P, Verrier JD, Nielsen JA, Johnson KR, Notterpek L, Hudson LD. Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci 2008;28:11720-30.
126. Fang X, Sun D, Wang Z, et al. MiR-30a positively regulates the inflammatory response of microglia in experimental autoimmune encephalomyelitis. Neurosci Bull 2017;33:603-15.
127. Volkmann I, Kumarswamy R, Pfaff N, et al. MicroRNA-mediated epigenetic silencing of sirtuin1 contributes to impaired angiogenic responses. Circ Res 2013;113:997-1003.
128. Liu XS, Chopp M, Pan WL, et al. MicroRNA-146a promotes oligodendrogenesis in stroke. Mol Neurobiol 2017;54:227-37.
129. Ma Q, Matsunaga A, Ho B, Oksenberg JR, Didonna A. Oligodendrocyte-specific argonaute profiling identifies microRNAs associated with experimental autoimmune encephalomyelitis. J Neuroinflammation 2020;17:297.
130. Li JS, Yao ZX. MicroRNAs: novel regulators of oligodendrocyte differentiation and potential therapeutic targets in demyelination-related diseases. Mol Neurobiol 2012;45:200-12.
131. Hinojosa-Godinez A, Jave-Suarez LF, Flores-Soto M, et al. Melatonin modifies SOX2+ cell proliferation in dentate gyrus and modulates SIRT1 and MECP2 in long-term sleep deprivation. Neural Regen Res 2019;14:1787-95.
132. Miguel-Hidalgo JJ, Hall KO, Bonner H, et al. MicroRNA-21: expression in oligodendrocytes and correlation with low myelin mRNAs in depression and alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 2017;79:503-14.
133. Koelsch KA, Webb R, Jeffries M, et al. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J Autoimmun 2013;41:168-74.
134. Afrang N, Tavakoli R, Tasharrofi N, et al. A critical role for miR-184 in the fate determination of oligodendrocytes. Stem Cell Res Ther 2019;10:112.
135. Belichenko PV, Wright EE, Belichenko NP, et al. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol 2009;514:240-58.
136. Zlatic SA, Duong D, Gadalla KKE, et al. Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome. iScience 2022;25:104966.
137. Aldosary M, Al-Bakheet A, Al-Dhalaan H, et al. Rett syndrome, a neurodevelopmental disorder, whole-transcriptome, and mitochondrial genome multiomics analyses identify novel variations and disease pathways. OMICS 2020;24:160-71.
138. Dave A, Pillai PP. Docosahexaenoic acid increased MeCP2 mediated mitochondrial respiratory complexes II and III enzyme activities in cortical astrocytes. J Biochem Mol Toxicol 2022;36:e23002.
139. Zlatic SA, Werner E, Surapaneni V, et al. Systemic metabolic and mitochondrial defects in rett syndrome models. bioRxiv ;2023:2023.
140. Gold WA, Williamson SL, Kaur S, et al. Mitochondrial dysfunction in the skeletal muscle of a mouse model of Rett syndrome (RTT): implications for the disease phenotype. Mitochondrion 2014;15:10-7.
141. Durand T, De Felice C, Signorini C, et al. F(2)-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. Biochimie 2013;95:86-90.
142. Poitelon Y, Kopec AM, Belin S. Myelin Fat Facts: An overview of lipids and fatty acid metabolism. Cells 2020;9:812.
143. Marangon D, Boccazzi M, Lecca D, Fumagalli M. Regulation of oligodendrocyte functions: targeting lipid metabolism and extracellular matrix for myelin repair. J Clin Med 2020;9:470.
144. De Felice C, Della Ragione F, Signorini C, et al. Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. Neurobiol Dis 2014;68:66-77.
145. Filosa S, Pecorelli A, D'Esposito M, Valacchi G, Hajek J. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome. Free Radic Biol Med 2015;88:81-90.
146. Nance E, Kambhampati SP, Smith ES, et al. Dendrimer-mediated delivery of N-acetyl cysteine to microglia in a mouse model of Rett syndrome. J Neuroinflammation 2017;14:252.
147. Li N, Zhang T, He M, Mu Y. MeCP2 attenuates cardiomyocyte hypoxia/reperfusion-induced injury via regulation of the SFRP4/Wnt/β-catenin axis. Biomarkers 2021;26:363-70.
148. Benjamins JA, Nedelkoska L, Lisak RP. Melanocortin receptor subtypes are expressed on cells in the oligodendroglial lineage and signal ACTH protection. J Neurosci Res 2018;96:427-35.
149. Nissanka N, Moraes CT. Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease. FEBS Lett 2018;592:728-42.
150. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010;12:125-69.
151. Shulyakova N, Andreazza AC, Mills LR, Eubanks JH. Mitochondrial dysfunction in the pathogenesis of Rett syndrome: implications for mitochondria-targeted therapies. Front Cell Neurosci 2017;11:58.
152. Can K, Menzfeld C, Rinne L, et al. Neuronal redox-imbalance in Rett syndrome affects mitochondria as well as cytosol, and is accompanied by intensified mitochondrial O (2) consumption and ROS release. Front Physiol 2019;10:479.
153. Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol 2006;26:5033-42.
154. Rone MB, Cui QL, Fang J, et al. Oligodendrogliopathy in multiple sclerosis: low glycolytic metabolic rate promotes oligodendrocyte survival. J Neurosci 2016;36:4698-707.
155. Lichvarova L, Blum W, Schwaller B, Szabolcsi V. Parvalbumin expression in oligodendrocyte-like CG4 cells causes a reduction in mitochondrial volume, attenuation in reactive oxygen species production and a decrease in cell processes’ length and branching. Sci Rep 2019;9:10603.
156. Dong Q, Liu Q, Li R, et al. Mechanism and consequence of abnormal calcium homeostasis in Rett syndrome astrocytes. Elife 2018:7.
157. Pecorelli A, Cervellati C, Cordone V, Hayek J, Valacchi G. Compromised immune/inflammatory responses in Rett syndrome. Free Radic Biol Med 2020;152:100-6.
158. Mehler MF, Kessler JA. Hematolymphopoietic and inflammatory cytokines in neural development. Trends Neurosci 1997;20:357-65.
159. Derecki NC, Cronk JC, Kipnis J. The role of microglia in brain maintenance: implications for Rett syndrome. Trends Immunol 2013;34:144-50.
160. Derecki NC, Cronk JC, Lu Z, et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012;484:105-9.
161. Cronk JC, Derecki NC, Ji E, et al. Methyl-CpG binding protein 2 regulates microglia and macrophage gene expression in response to inflammatory stimuli. Immunity 2015;42:679-91.
162. Bonora M, De Marchi E, Patergnani S, et al. Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process. Cell Death Differ 2014;21:1198-208.
163. Feldhaus B, Dietzel ID, Heumann R, Berger B. [Corticoids protect oligodentrocyte precursor cells against cytokine-induced damage]. Zentralbl Gynakol 2004;126:282-5.
164. Pecorelli A, Cervellati F, Belmonte G, et al. Cytokines profile and peripheral blood mononuclear cells morphology in Rett and autistic patients. Cytokine 2016;77:180-8.
165. Leoncini S, De Felice C, Signorini C, et al. Cytokine dysregulation in MECP2- and CDKL5-related Rett syndrome: relationships with aberrant redox homeostasis, inflammation, and ω-3 PUFAs. Oxid Med Cell Longev 2015;2015:421624.
166. Ding X, Cao F, Cui L, Ciric B, Zhang GX, Rostami A. IL-9 signaling affects central nervous system resident cells during inflammatory stimuli. Exp Mol Pathol 2015;99:570-4.
167. Liu H, Yang X, Yang J, et al. IL-17 Inhibits oligodendrocyte progenitor cell proliferation and differentiation by increasing K+ channel Kv1.3. Front Cell Neurosci 2021;15:679413.
168. Li Y, Liu L, Ding X, Liu Y, Yang Q, Ren B. Interleukin-1β attenuates the proliferation and differentiation of oligodendrocyte precursor cells through regulation of the microRNA-202-3p/β-catenin/Gli1 axis. Int J Mol Med 2020;46:1217-24.
169. Zeis T, Enz L, Schaeren-Wiemers N. The immunomodulatory oligodendrocyte. Brain Res 2016;1641:139-48.
170. Moyon S, Dubessy AL, Aigrot MS, et al. Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. J Neurosci 2015;35:4-20.
171. Zveik O, Fainstein N, Rechtman A, et al. Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells. Glia 2022;70:1191-209.
172. Zhou B, Zhu Z, Ransom BR, Tong X. Oligodendrocyte lineage cells and depression. Mol Psychiatry 2021;26:103-17.
173. Kishi N, MacDonald JL, Ye J, Molyneaux BJ, Azim E, Macklis JD. Reduction of aberrant NF-κB signalling ameliorates Rett syndrome phenotypes in Mecp2-null mice. Nat Commun 2016;7:10520.
174. Falcão AM, van Bruggen D, Marques S, et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med 2018;24:1837-44.
175. Antel JP, Lin YH, Cui QL, et al. Immunology of oligodendrocyte precursor cells in vivo and in vitro. J Neuroimmunol 2019;331:28-35.
176. Kilanczyk E, Saraswat Ohri S, Whittemore SR, Hetman M. Antioxidant protection of NADPH-Depleted oligodendrocyte precursor cells is dependent on supply of reduced glutathione. ASN Neuro 2016;8:175909141666040.
177. Orduz D, Maldonado PP, Balia M, et al. Interneurons and oligodendrocyte progenitors form a structured synaptic network in the developing neocortex. Elife 2015:4.
178. Orduz D, Benamer N, Ortolani D, et al. Developmental cell death regulates lineage-related interneuron-oligodendroglia functional clusters and oligodendrocyte homeostasis. Nat Commun 2019;10:4249.
179. Mount CW, Yalçın B, Cunliffe-Koehler K, Sundaresh S, Monje M. Monosynaptic tracing maps brain-wide afferent oligodendrocyte precursor cell connectivity. Elife 2019:8.
180. Birey F, Kloc M, Chavali M, et al. Genetic and Stress-induced loss of NG2 glia triggers emergence of depressive-like behaviors through reduced secretion of FGF2. Neuron 2015;88:941-56.
